Mr Chris Blick

Mr Chris Blick is a consultant urological and robotic surgeon who has a subspeciality interest in benign prostate conditions and urological cancers.

He is a key opinion leader in novel surgical technologies and in the treatment of benign prostatic enlargement offering Aquablation, Rezum, iTind and Echolaser as well as TURP. He is among the UK’s highest volume aquablation surgeons and has presented his outcome data internationally.

Mr Blick has extensive experience in the management of inflammatory conditions and infections affecting the urinary tract and prostate (prostatitis). He contributed to landmark clinical trials demonstrating the efficacy of the uromune vaccine in recurrent urinary tract infections.

With over a decade of experience in robotic surgery, Mr Blick routinely performs complex procedures using the Da Vinci surgical system, including nephrectomy (kidney removal), partial nephrectomy, pyeloplasty, partial cystectomy, and ureteric re-implantation.

Deeply involved in clinical research, Mr Blick became the first urological trainee member of the National Institute of Heath Research (NIHR) clinical studies group (CSG). He has been a member of the national renal and bladder cancer CSG, the screening and early prevention (SPED) group and the UK cancer screening and early prevention group of the NIHR.

Mr Blick is the Research and Development Lead in Urology at the Royal Berkshire Hospital. He has recently received funding and was Chief Investigator in the TARGET trial using augmented reality and artificial intelligence in the diagnosis of prostate cancer. He currently runs a PhD programme evaluating the role of remote monitoring, machine learning and AI in Urological conditions. 

In addition, Mr Blick is the UK Chief Investigator for the EASE trial, evaluating active surveillance in renal cancer, and serves as Principal Investigator for several national and international studies in bladder, renal, and prostate cancer.